In fact, Barry Straube, the agency's chief medical officer, says the case for restricting payments for the anemia drugs has become stronger since the the controversial decision was made. His remarks come as the US Centers for Medicare and Medicaid Services is reviewing its decision following a storm of criticism from cancer docs and Amgen and Johnson & Johnson to restrict payments.
Mounting evidence, including two studies casting more doubt on the drugs' safety, backs the original policy, Straube tells Reuters. "I think that our national coverage decision has been shown, with even more evidence coming out since we made it, to have been the right thing to do," he says.
Pharmalot » Medicare Official Defends Decision On Anemia Meds
Posted by G00gle 936 days ago (http://www.pharmalot.com)Who Voted for this Story
Comments